The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
LNH-84 regimen: a multicenter study of intensive chemotherapy in 737 patients with aggressive malignant lymphoma.
Abstract
From July 1984 to September 1987, 737 patients with aggressive malignant lymphoma (ML) were treated by an intensive regimen (LNH-84) comprising three or four courses of doxorubicin, 75 mg/m2; cyclophosphamide, 1,200 mg/m2; vindesine, 2 mg/m2 x 2; bleomycin, 10 mg x 2; and prednisolone, 60 mg/m2 x 5 (ACVB), consolidation with high-dose methotrexate, ifosfamide, etoposide, asparaginase, and cytarabine, and a randomized late intensification with two courses of cytarabine, cyclophosphamide, teniposide, bleomycin, and prednisone (AraCVmB). Four hundred forty-two patients had intermediate-grade ML, 221 highgrade ML, and 74 unclassified ML. Most of the patients had advanced disease: stage IIE (23%), III (13%), or IV (47%); 38% disseminated nodes; 38% two or more extranodal sites; and 41% a tumoral mass greater than 10 cm. Five hundred fifty-three patients (75%) went into complete remission (CR), 63 (9%) into partial remission, 62 (8%) failed to respond, and 59 (8%) died during ACVB courses, 17 of them from progression of the disease. With a median follow-up of 23 months, the estimated 2-year overall survival time to failure (TTF), and time to relapse (TTR) survival are 67%, 56%, and 67%, respectively. Patients receiving a late intensification had the same relapse rate as the other patients. A persistent fibronecrotic mass was found in 150 patients (20%) and did not influence the relapse rate. Toxicity was mainly neutropenia and infection during the ACVB courses, with 40 patients (5%) dying from septic complications while responding to treatment. Fifty-three percent of the patients had a neutropenia less than 0.500 x 10(9)/L, 58% fever (6% grade 4), and 49% a documented infection (8% grade 4). These results obtained with the LNH-84 regimen demonstrate that this therapeutic scheme is an effective treatment for aggressive ML.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1992) · Springer Series in Statistics · doi:10.1007/978-1-4612-4380-9_25 · Cited by 45,181
(2008) · The Concise Encyclopedia of Statistics · doi:10.1007/978-0-387-32833-1_5 · Cited by 2,670
Plackett, R. L., & Cox, D. R. (1971) · Journal of the Royal Statistical Society. Series A (General) · doi:10.2307/2344247 · Cited by 2,264
Stein, H., Mason, D., Gerdes, J., O'Connor, N., Wainscoat, J., Pallesen, G., Gatter, K., Falini, B., Delsol, G., Lemke, H., et al. (1985) · Blood · doi:10.1182/blood.v66.4.848.848 · Cited by 1,846
MACOP-B Chemotherapy for the Treatment of Diffuse Large-Cell Lymphoma
KLIMO, P., & CONNORS, J. M. (1985) · Annals of Internal Medicine · doi:10.7326/0003-4819-102-5-596 · Cited by 664
SHIPP, M. A., HARRINGTON, D. P., KLATT, M. M., JOCHELSON, M. S., PINKUS, G. S., MARSHALL, J. L., ROSENTHAL, D. S., SKARIN, A. T., & CANELLOS, G. P. (1986) · Annals of Internal Medicine · doi:10.7326/0003-4819-104-6-757 · Cited by 277
Jagannath, S., Velasquez, W. S., Tucker, S. L., Fuller, L. M., McLaughlin, P. W., Manning, J. T., North, L. B., & Cabanillas, F. C. (1986) · Journal of Clinical Oncology · doi:10.1200/jco.1986.4.6.859 · Cited by 186
Cited by
Hermine, O., Haioun, C., Lepage, E., d'Agay, M., Briere, J., Lavignac, C., Fillet, G., Salles, G., Marolleau, J., Diebold, J., et al. (1996) · Blood · doi:10.1182/blood.v87.1.265.265 · Cited by 452
Gisselbrecht, C., Gaulard, P., Lepage, É., Coiffier, B., Brière, J., Haïoun, C., Cazals-Hatem, D. L., Bosly, A., Xerri, L., Tilly, H., et al. (1998) · PubMed · doi:10.1182/blood.v92.1.76.413a19_76_82 · Cited by 437
Self-citationHaioun, C., Lepage, E., Gisselbrecht, C., Salles, G., Coiffier, B., Brice, P., Bosly, A., Morel, P., Nouvel, C., Tilly, H., et al. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.16.3025 · Cited by 421
Self-citationJuweid, M. E., Wiseman, G. A., Vose, J. M., Ritchie, J. M., Menda, Y., Wooldridge, J. E., Mottaghy, F. M., Rohren, E. M., Blumstein, N. M., Stolpen, A., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.01.891 · Cited by 387
Prognostic significance of survivin expression in diffuse large B-cell lymphomas.
Adida, C., Haïoun, C., Gaulard, P., Lepage, É., Morel, P., Brière, J., Dombret, H., Reyes, F., Diebold, J., Gisselbrecht, C., et al. (2000) · PubMed · doi:10.1182/blood.v96.5.1921 · Cited by 359
Self-citation
Metadata
- Authors
- Coiffier, B., Gisselbrecht, C., Herbrecht, R., Tilly, H., Bosly, A., & Brousse, N.
- Venue
- Journal of Clinical Oncology
- Published
- 1989-08
- Volume
- 7
- Issue
- 8
- Pages
- 1018-1026
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W1896652710
- Cited by
- 254
- References
- 7
- Type
- conference abstract
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: LNH-84 regimen: a multicenter study of intensive chemotherapy in 737 patients with aggressive malignant lymphoma. https://app.cochat.ai/papers/10.1200/jco.1989.7.8.1018
- The paper
- Coiffier, B., Gisselbrecht, C., Herbrecht, R., Tilly, H., Bosly, A., & Brousse, N. (1989). LNH-84 regimen: a multicenter study of intensive chemotherapy in 737 patients with aggressive malignant lymphoma. Journal of Clinical Oncology. https://doi.org/10.1200/jco.1989.7.8.1018
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.